Titre du document / Document title

Fluoxetine in the treatment of premenstrual dysphoria

Auteur(s) / Author(s)

Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group (Commanditaire)
STEINER M. ⁽¹⁾ ; STEINBERG S. ; STEWART D. ; CARTER D. ; BERGER C. ; REID R. ; GROVER D. ; STREINER D. ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ McMaster univ., St. Joseph's hosp., dep. psychiatry and biomedical sci., Hamilton ON L8N 4A6, CANADA

Résumé / Abstract

Background. Premenstrual dysphoria shares certain features with depression and anxiety states, which have been linked to serotonergic dysregulation. We evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria. Methods. The trial consisted of a single-blind, placebo washout period lasting two menstrual cycles, followed by a randomized, double-blind, placebo-controlled trial of fluoxetine at a dose of either 20 mg or 60 mg per day or placebo for six menstrual cycles. Healthy women meeting criteria for what was then called late-luteal-phase dysphoric disorder were recruited at seven university-affiliated women's health clinics in Canada. The primary outcome measure consisted of visual-analogue scales for tension, irritability, and dysphoria during the late luteal phase of each cycle. Results. Of 405 women enrolled in the placebo washout period, 313 subsequently entered the randomized phase of the study, which lasted six menstrual cycles, and 180 completed it. Fluoxetine at a dose of 20 or 60 mg per day was significantly superior to placebo in reducing symptoms of tension, irritability, and dysphoria, as measured by the visual-analogue scales (P<0.001). The women who received 60 mg of fluoxetine per day reported significantly more side effects than those who received 20 mg per day or placebo (P<0.001). Conclusions. Fluoxetine is useful in the treatment of premenstrual dysphoria. Treatment with fluoxetine at a dose of 20 mg per day reduces the potential for side effects while maximizing therapeutic efficacy

Revue / Journal Title

The New England journal of medicine   ISSN 0028-4793   CODEN NEJMAG 

Source / Source

1995, vol. 332, n^o23, pp. 1529-1534 (58 ref.)

Langue / Language

Anglais

Editeur / Publisher

Massachusetts Medical Society, Boston, MA, ETATS-UNIS  (1928) (Revue)

Mots-clés anglais / English Keywords

Depression ; Association ; Anxiety ; Premenstrual syndrome ; Treatment ; Symptomatology ; Treatment efficiency ; Bibliographic survey ; Human ; Female ; Psychopathology ; Female genital diseases ; Menstruation disorders ;

Mots-clés français / French Keywords

Etat dépressif ; Association ; Angoisse anxiété ; Prémenstruel syndrome ; Traitement ; Fluoxétine ; Symptomatologie ; Efficacité traitement ; Synthèse bibliographique ; Homme ; Femelle ; Psychopathologie ; Appareil génital femelle pathologie ; Cycle menstruel pathologie ;

Mots-clés espagnols / Spanish Keywords

Estado depresivo ; Asociación ; Angustia ansiedad ; Premenstrual síndrome ; Tratamiento ; Sintomatología ; Eficacia tratamiento ; Síntesis bibliográfica ; Hombre ; Hembra ; Psicopatología ; Aparato genital hembra patología ; Ciclo menstrual patología ;

Localisation / Location

INIST-CNRS, Cote INIST : 6013, 35400005102000.0010